FDA Commissioner Marty Makary (Photo by Tasos Katopodis/Getty Images for Semafor)

June 17, 2025 01:24 PM EDTUpdated 02:51 PM

FDA unveils one-year pilot to speed some new drugs to market in just one month

Zachary Brennan

Senior Editor

A new FDA pilot program unveiled Tuesday aims to significantly cut drug review times to support what Commissioner Marty Makary deems “national priorities.”

The one …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA unveils one-year pilot to speed some new drugs to market in just one month

Zachary Brennan

Senior Editor

Sign up to read this article for free.

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

Orphan drug, PBM changes are excluded from Senate version of Trump tax bill

Members of Congress oppose NIH's payment cut plan, urge appeals court to maintain block

Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B

Dyne pivots on primary endpoint, delays filing for DM1 drug

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

Or­phan drug, PBM changes are ex­clud­ed from Sen­ate ver­sion of Trump tax bill

Mem­bers of Con­gress op­pose NI­H's pay­ment cut plan, urge ap­peals court to main­tain block

Lil­ly to bol­ster gene edit­ing pipeline, buy­ing Verve for up to $1.3B

Dyne piv­ots on pri­ma­ry end­point, de­lays fil­ing for DM1 drug

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

FDA unveils one-year pilot to speed some new drugs to market in just one month

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

Orphan drug, PBM changes are excluded from Senate version of Trump tax bill

Members of Congress oppose NIH's payment cut plan, urge appeals court to maintain block

Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B

Dyne pivots on primary endpoint, delays filing for DM1 drug

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?